Clinical Trials Directory

Trials / Completed

CompletedNCT01486316

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Integrated Diagnostic Evaluation in Non-Therapy DevIces For the studY of Heart Failure

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Medtronic Cardiac Rhythm and Heart Failure · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to characterize the feasibility and impact of a diagnostic tool that may help clinicians identify when patients are at higher risk of visiting the hospital for a heart failure event. The study will use a non-experimental device that is inserted just under the skin of the chest, which continuously monitors the heart rhythm in combination with an experimental web-based heart failure risk status. Patients with atrial fibrillation and heart failure will be evaluated to collect data about the potential of this risk status to help improve patient outcome.

Conditions

Interventions

TypeNameDescription
DEVICEReveal XT® Insertable Cardiac MonitorIf not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
OTHERHeart Failure Risk Status DiagnosticThe experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity. Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: "Low", "Medium", "High", or "Very High".

Timeline

Start date
2011-11-01
Primary completion
2014-12-01
Completion
2015-02-01
First posted
2011-12-06
Last updated
2018-07-12
Results posted
2018-07-12

Locations

11 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01486316. Inclusion in this directory is not an endorsement.